Sangamo Therapeutics (SGMO) Misses Q1 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UPDATE: RBC Capital Starts Sangamo BioSciences (SGMO) at Outperform
May 3, 2021 4:12 PM EDT(Updated - May 3, 2021 4:15 PM EDT)
RBC Capital analyst Luca Issi initiates coverage on Sangamo BioSciences (NASDAQ: SGMO) with a Outperform rating and a price target of $22.00 (from $26.00).
The analyst comments "SGMO has trail blazed the field of gene-editing using zinc... More
